Form 4: Regenxbio Director Alexandra Glucksmann Reports Stock and Option Transactions

Director Alexandra Glucksmann reports acquisition of common stock and stock options in Regenxbio Inc.

Summary

• On May 31, 2024, Alexandra Glucksmann, a director of REGENXBIO Inc., reported transactions involving the company's securities.
• Glucksmann acquired 4,790 shares of common stock related to a restricted stock unit award at $0.00.
• These shares will vest on May 1, 2025, contingent upon continued service to the Issuer.
• Glucksmann also acquired 24,454 stock options with an exercise price of $14.35.
• These options vest in 12 equal monthly installments starting May 31, 2024, also subject to continuous service.
• Following these transactions, Glucksmann directly owns 11,286 shares of common stock and 24,454 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard SEC filing reporting insider transactions. The acquisition of shares and options by a director can be seen as a mildly positive sign, but it's not a major event.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, common in the biopharmaceutical industry where stock options and RSUs are frequently used as part of compensation packages.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard compensation practices in the biotechnology industry, used to align the interests of executives and directors with those of shareholders.
• Vesting schedules, such as the 12-month monthly vesting for the options and the single vesting date for the RSU, are typical in the industry.
• Comparing the size of the option grant to those of directors at similar-sized biotech companies (e.g., companies with market caps between $1-5 billion) would provide further context.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment, as they reflect a director's investment in the company.

Key Dates